|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.85 USD | +0.19% |
|
-0.69% | -2.56% |
| Dec. 12 | US FDA approves Innoviva's oral antibiotic for gonorrhea | RE |
| Dec. 12 | Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 | CI |
Business description: Pfizer Inc.
- primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (24.5%);
- other (1.9%).
The United States accounts for 60.8% of net sales.
Number of employees: 81,000
Sales by Activity: Pfizer Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biopharma | 41.91B | 79.56B | 98.99B | 57.19B | 62.4B |
Pfizer Centreone | - | - | - | - | 1.15B |
Pfizer Ignite | - | - | - | - | 82M |
Other business activities | - | 1.73B | 1.34B | 1.31B | - |
Geographical breakdown of sales: Pfizer Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 21.71B | 29.75B | 42.47B | 27.09B | 38.69B |
Developed Markets | - | - | - | - | 16.06B |
Emerging Markets | 8.37B | 20.7B | 20.1B | 12B | 8.88B |
Developed Europe | 7.79B | 18.34B | 21.98B | 11.65B | - |
International | 4.04B | 12.51B | 15.78B | 7.76B | - |
Executive Committee: Pfizer Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 63 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 60 | 2022-05-01 |
| Chief Tech/Sci/R&D Officer | - | 2025-02-23 | |
| Chief Tech/Sci/R&D Officer | - | 2006-12-31 | |
James F List
CTO | Chief Tech/Sci/R&D Officer | - | 2025-03-05 |
Composition of the Board of Directors: Pfizer Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 67 | 2007-08-31 |
Shantanu Narayen
BRD | Director/Board Member | 61 | 2013-09-26 |
Albert Bourla
CHM | Chairman | 63 | 2019-12-31 |
Jim Smith
BRD | Director/Board Member | 65 | 2014-06-25 |
| Director/Board Member | 68 | 2015-06-24 | |
Ronald Blaylock
BRD | Director/Board Member | 65 | 2017-02-22 |
Dan Littman
BRD | Director/Board Member | 72 | 2018-03-04 |
Scott Gottlieb
BRD | Director/Board Member | 53 | 2019-06-26 |
James Quincey
BRD | Director/Board Member | 60 | 2020-02-26 |
Susan Hockfield
BRD | Director/Board Member | 74 | 2020-03-03 |
Holdings: Pfizer Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
PFIZER LIMITED 63.92% | 29,243,042 | 63.92% | 1,625,134,685 $ |
BIONTECH SE 0.69% | 1,658,361 | 0.69% | 171,059,937 $ |
CSTONE PHARMACEUTICALS 7.85% | 115,928,803 | 7.85% | 90,978,606 $ |
| 5,376,344 | 5.52% | 63,870,967 $ | |
VALNEVA 5.56% | 9,554,395 | 5.56% | 44,619,502 $ |
ARVINAS, INC. 5.38% | 3,457,815 | 5.38% | 43,516,602 $ |
PYXIS ONCOLOGY, INC. 11.3% | 7,032,770 | 11.3% | 36,500,076 $ |
CELCUITY INC. 0.76% | 349,406 | 0.76% | 35,338,923 $ |
| 22,032,040 | 9.8% | 32,166,778 $ | |
WAVE LIFE SCIENCES LTD. 1.12% | 1,875,000 | 1.12% | 14,550,000 $ |
Company details: Pfizer Inc.
Group companies: Pfizer Inc.
| Name | Category and Sector |
|---|---|
Pfizer PFE Italy Holdco SARL | |
Pfizer Europe Holdings SARL
 Pfizer Europe Holdings SARL Functions as an investment holding company | |
Pfizer Group Luxembourg SARL
 Pfizer Group Luxembourg SARL Provides miscellaneous intermediation services | |
Pfizer Group Luxembourg SARL
Pfizer Group Luxembourg SARL Provides miscellaneous intermediation services | |
Pfizer Ireland Pharmaceuticals ULC
 Pfizer Ireland Pharmaceuticals ULC Provides financial intermediation services |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.19% | -0.69% | +1.06% | -51.29% | 147B | |
| +1.80% | +1.70% | +30.21% | +186.49% | 920B | |
| +0.75% | +4.78% | +44.31% | +18.06% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.52% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.11% | 340B | |
| -1.12% | -1.09% | +28.43% | +18.70% | 278B | |
| -0.45% | -1.48% | +20.24% | +24.41% | 254B | |
| +1.30% | +0.58% | -1.67% | -9.57% | 249B | |
| +0.45% | +3.73% | -57.41% | -30.85% | 224B | |
| +0.11% | -3.68% | +17.41% | +16.70% | 171B | |
| Average | +0.24% | +0.45% | +13.65% | +21.13% | 348.89B | |
| Weighted average by Cap. | +0.53% | +1.07% | +20.98% | +55.40% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
- Company Pfizer Inc.
Select your edition
All financial news and data tailored to specific country editions
